North Bay Business Journal

Monday, February 8, 2010, 4:24 am

Medical device startup Osseon gets traction


Print Friendly Print Friendly    

Share this item

    Company’s  treatment  for spinal fractures  gaining attention

    Osseon Therapeutics' flexible needle allows it to pinpoint vertebral fractions and deliver bone cement.

    Osseon Therapeutics' flexible needle allows it to pinpoint vertebral fractions and deliver bone cement.

    SANTA ROSA – Medical device startup Osseon Therapeutics has reached break-even in three short years, and its bone cement delivery system is in high demand among physicians and surgery centers, said a company spokesman.

    After obtaining FDA approval and launching its Osseoflex system last year, Osseon has passed its 530th case and is one of only two companies approved for cavity creation (Osseoplasty) by Medicare. The other is Medtronic.

    The system was patented by Y. King Liu, a 40-year academic researcher, clinical practitioner and biomedical engineering device developer and the founder of the University of Northern California in Santa Rosa.

    Dr. Liu invented the delivery system in conjunction with longer-lasting bone cement for the performance of Kyphoplasty, a surgical procedure to repair vertebral bone.

    OsseonProductsLocal entrepreneur John Stalcup, now Osseon CEO, convinced him that both products should be commercially marketed.

    The U.S. market for minimally invasive treatment of spinal fractures is $650 million.

    Kyphoplasty, or Osseoplasty as Osseon has renamed it, primarily is used to treat compression fractures of the vertebral spine, the result of osteoporosis and other degenerative bone diseases and osteotraumatic injuries, conditions which produce a lot of pain.

    “Patients with compression fractures commonly report a pain level of 10, the very highest,” said Osseon Director of Marketing Mike Bivens. “After Osseoplasty, which can be performed in less than 10 minutes with our device, they walk away pain free.”

    OsseonFlexThe difference between Osseon’s delivery system and others lies in its flexible needle, which can be bent after insertion to target the fractured area and put the smallest necessary amount of cement in place.

    A procedure using the competing system costs about $41,000. Osseon brings it down to $24,000, he said.

    Such significant cost lowering for an oft-performed procedure has brought Osseon to the attention of the global medical community.

    The company has been setting up distributorships across the U.S., and lately distributors have been contacting Osseon on their own, said Mr. Bivens.

    “It’s an exciting time, to see a product which alleviates terrible pain take off in the marketplace,” said Mr. Bivens.

    Osseon is the first of several startups incubated at the University of Northern California to bring a product to market.

    Dr. Liu holds 13 patents. Osseon is currently developing a flexible drill for especially dense bone tissue.

    For more information visit www.osseon.com.

    Copyright © 1988–2015 North Bay Business Journal
    View the policy for linking to website content.

    Print Friendly Print Friendly    



    1. February 8, 2010, 10:11 am

      by Chris Vinson

      Congratulations Osseon Therapeutics! Keep up the great work. Sonoma County is proud of you.

    2. February 8, 2010, 11:45 am

      by mark reise

      This procedure does not address height restoration to stabilaze the spine? I had a balloon kyphoplasty which has data and studies to support the procedure. Are our doctors choosing cost over legitimized, scientific data? i hope not, otherwise we are definetely in a socialized health care system.

    3. February 8, 2010, 3:37 pm

      by Musculoskeletal Clinical Regulatory Advisers - Orthopedic News

      [...] Medical device startup Osseon gets traction [...]

    4. February 8, 2010, 7:06 pm

      by N

      Our surgeons are not making decisions based on cost – they leave that up to the hospitals. I have yet to meet a surgeon (as I am a ortho sales rep) that is more concerned about the cost then the outcome of the patient.

    Submit Your Comments


    Required, will not be published

    Comments are moderated and generally will be posted if they are on-topic and not abusive. For more information, please see our Comments and Letters Policy. To share this item by email or social media, use the links above.

    Do not use this form to contact people, companies or organizations mentioned in this story. Contact them directly. Private messages left here will be deleted.